PURPOSE: GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP) is a treatment option for lower urinary tract symptoms secondary to benign prostatic hyperplasia. We review our experience using the 120 W GreenLight HPS laser system. MATERIALS AND METHODS: We prospectively evaluated our experience with GreenLight HPS laser PVP. All patients who failed medical therapy underwent GreenLight HPS laser PVP (C.W.). All had American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men, American Society of Anesthesiologists risk score, serum prostate-specific antigen, maximum flow rate, and postvoid residual determinations and volumetric measurements with transrectal ultrasonography. Transurethral PVP was performed using a GreenLight HPS side-firing laser system. RESULTS: 170 consecutive patients were identified, having a mean age of 67.4±9.5 years. The mean prostate volume was 65.3±36.7 mL and mean American Society of Anesthesiologists score was 2.3±0.7. Mean laser time, operating time, and energy usage were 14.1±10.5 minutes, 33.5±24.7 minutes, and 95.0±72.3 kJ, respectively. All were outpatient procedures with 100 (58.8%) patients catheter-free at discharge. 35 (20.5%) and 26 (15.3%) patients had follow-up of 24 and 36 months, respectively. Eight (4.7%) patients developed a urinary tract infection. No bladder neck contracture or urethral stricture were reported. American Urological Association Symptom Score, Quality of Life, maximum flow rate, and postvoid residual showed immediate and stable improvement from baseline (p<0.05) that has been durable to 36 months. The Sexual Health Inventory for Men score did not change postoperatively. CONCLUSIONS: Our intermediate results suggest that GreenLight HPS laser PVP is safe, effective, and durable for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
PURPOSE: GreenLight HPS™ laser photoselective vaporization prostatectomy (PVP) is a treatment option for lower urinary tract symptoms secondary to benign prostatic hyperplasia. We review our experience using the 120 W GreenLight HPS laser system. MATERIALS AND METHODS: We prospectively evaluated our experience with GreenLight HPS laser PVP. All patients who failed medical therapy underwent GreenLight HPS laser PVP (C.W.). All had American Urological Association Symptom Score, Quality of Life score, Sexual Health Inventory for Men, American Society of Anesthesiologists risk score, serum prostate-specific antigen, maximum flow rate, and postvoid residual determinations and volumetric measurements with transrectal ultrasonography. Transurethral PVP was performed using a GreenLight HPS side-firing laser system. RESULTS: 170 consecutive patients were identified, having a mean age of 67.4±9.5 years. The mean prostate volume was 65.3±36.7 mL and mean American Society of Anesthesiologists score was 2.3±0.7. Mean laser time, operating time, and energy usage were 14.1±10.5 minutes, 33.5±24.7 minutes, and 95.0±72.3 kJ, respectively. All were outpatient procedures with 100 (58.8%) patients catheter-free at discharge. 35 (20.5%) and 26 (15.3%) patients had follow-up of 24 and 36 months, respectively. Eight (4.7%) patients developed a urinary tract infection. No bladder neck contracture or urethral stricture were reported. American Urological Association Symptom Score, Quality of Life, maximum flow rate, and postvoid residual showed immediate and stable improvement from baseline (p<0.05) that has been durable to 36 months. The Sexual Health Inventory for Men score did not change postoperatively. CONCLUSIONS: Our intermediate results suggest that GreenLight HPS laser PVP is safe, effective, and durable for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Authors: Woong Jin Bae; Sun Gook Ahn; Jun Ho Bang; Jang Ho Bae; Yong Sun Choi; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Sae Woong Kim Journal: Korean J Urol Date: 2013-01-18